

National Lieutenant Governors Association

Resolution Supporting the Use of Opioid Abatement Funds

- 2 WHEREAS, provisional data from the CDC's National Center for Health Statistics indicate there were an
- 3 estimated 100,036 drug overdose death in the United States during a 12-month period ending in April
- 4 2021, an increase of 28.5% from the 78,056 deaths during the year before¹, and
- 5 WHEREAS, the new data documents that estimated overdose death from opioids increased to 75,673 in
- 6 the same period, up from 56,064 the year before², and
- 7 WHEREAS, nationwide settlements have been reached to resolve opioid litigation brought by states and
- 8 local political subdivisions against parties involved in the process of opioid manufacturing and
- 9 distribution, and

1

- 10 WHEREAS, these settlements, if agreed and adopted, will provide substantial funds to states and
- subdivisions for abatement of the opioid epidemic across the country and will impose transformative
- 12 changes in the way the settling defendants conduct their business³.
- 13 NOW, THEREFORE, BE IT RESOLVED that the National Lieutenant Governors Association (NLGA)
- 14 supports multiple strategies to address the opioid epidemic and appropriate use of opioid abatement funds.
- 15 **BE IT FURTHER RESOLVED** that the NLGA supports the use of Naloxone or other FDA-approved
- drugs to reverse opioid overdoses and increase distribution to individuals who are uninsured or whose
- 17 insurance does not cover the service⁴.
- 18 **BE IT FURTHER RESOLVED** that the NLGA supports expanding the availability of treatment for
- 19 OUD and any co-occurring SUD/MH conditions, including all forms of Medication-Assisted Treatment
- 20 ("MAT") approved by the U.S. Food and Drug Administration⁵.
- 21 **BE IT FURTHER RESOLVED** that the NLGA supports funding to expand warm hand-off programs and
- 22 recovery services such as navigators and on-call teams in hospital emergency departments; and
- 23 comprehensive wrap-around services which may include housing, transportation, job placement/training
- 24 and childcare⁶.

¹ https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm

² https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm

³ https://nationalopioidsettlement.com/

⁴ https://nationalopioidsettlement.com/wp-content/uploads/2021/12/Final-Distributor-Settlement-Agreement-12.23.21 Exhibit-Updates.pdf page 120

⁵ https://nationalopioidsettlement.com/wp-content/uploads/2021/12/Final-Distributor-Settlement-Agreement-12.23.21 Exhibit-Updates.pdf page123

⁶ https://nationalopioidsettlement.com/wp-content/uploads/2021/12/Final-Distributor-Settlement-Agreement-12.23.21 Exhibit-Updates.pdf page 121



National Lieutenant Governors Association

- 25 **BE IT FURTHER RESOLVED** that the NLGA supports funding to provide evidence-based treatment
- 26 and recovery support, for persons with OUD and co-occurring SUD/MH disorder within and transitioning
- 27 out of the criminal justice system.⁷
- 28 **BE IT FURTHER RESOLVED** that the NLGA supports funding for evidence-based prevention
- 29 programs in schools; medical provider education regarding best prescribing practices for opioids;
- 30 community drug disposal programs and post-overdose response teams or similar strategies that connect
- 31 individuals to behavioral health services and supports⁸.
- 32 **BE IT FURTHER RESOLVED** that the NLGA supports evidence-based data collection and research
- analyzing the effectiveness of the abatement strategies within each state⁹.

ADOPTED, this day, the 22nd of July, 2022.

Sponsors: Lt. Governor Bethany Hall-Long (D – Delaware), Lt. Governor Boyd Rutherford (R – Maryland)

https://nationalopioidsettlement.com/wp-content/uploads/2021/12/Final-Distributor-Settlement-Agreement-12.23.21 Exhibit-Updates.pdf page122

⁸ https://nationalopioidsettlement.com/wp-content/uploads/2021/12/Final-Distributor-Settlement-Agreement-12.23.21 Exhibit-Updates.pdf page122

⁹ https://nationalopioidsettlement.com/wp-content/uploads/2021/12/Final-Distributor-Settlement-Agreement-12.23.21 Exhibit-Updates.pdf page122